INmune Bio INMB

$ 4.78 0.42%

Quarterly report 2024-Q3
added 10-31-2024

INmune Bio Balance Sheet 2011-2024 | INMB

Annual Balance Sheet INmune Bio

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-35.3 M	-42.4 M	-74 M	-21.8 M	-6.83 M	-186 K	-1.37 M	208 K	-	-	-	-	-
Long Term Debt	397 K	9.7 M	704 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	119 K	87 K	72 K	33.9 K	8.29 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	126 K	160 K	-	-	-	-	-	-	-	-
Total Current Liabilities	18.5 M	10.9 M	4.36 M	1.78 M	700 K	-	-	-	-	-	-	-	-
Total Liabilities	18.9 M	21.7 M	19.7 M	1.9 M	861 K	824 K	310 K	601 K	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-121 M	-91 M	-63.7 M	-33.4 M	-21.3 M	-13.6 M	-1.16 M	-326 K	-	-	-	-	-
Total Assets	57 M	81.8 M	99.9 M	40.7 M	24.5 M	17.4 M	18.4 M	452 K	-	-	-	-	-
Cash and Cash Equivalents	35.8 M	52.2 M	74.8 M	22 M	7 M	186 K	1.37 M	-	-	-	-	-	-
Book Value	38.1 M	60.1 M	80.2 M	38.8 M	23.6 M	16.5 M	18.1 M	-149 K	-	-	-	-	-
Total Shareholders Equity	37.3 M	60.1 M	80.2 M	38.8 M	23.6 M	16.5 M	18.1 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet INmune Bio

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	284 K	322 K	397 K	12.5 M	15 M	15 M	526 K	15 M	-	15 M	704 K	15 M	14.3 M	116 K	126 K	126 K	126 K	126 K	160 K	160 K	160 K	160 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	14.1 M	15.4 M	18.9 M	18 M	19.1 M	18.7 M	21.7 M	20.1 M	-	18.7 M	19.7 M	19.4 M	17.5 M	2.31 M	1.9 M	1.9 M	1.9 M	1.9 M	861 K	861 K	861 K	861 K	824 K	824 K	824 K	824 K	310 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-154 M	-142 M	-121 M	-113 M	-104 M	-97.6 M	-91 M	-85.2 M	-	-70.6 M	-63.7 M	-54 M	-44.6 M	-37.9 M	-33.4 M	-33.4 M	-33.4 M	-33.4 M	-21.3 M	-21.3 M	-21.3 M	-21.3 M	-13.6 M	-13.6 M	-13.6 M	-13.6 M	-1.16 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	52.8 M	52.5 M	57 M	62.7 M	69.7 M	74 M	81.8 M	83.8 M	-	94.4 M	99.9 M	108 M	60.7 M	65.9 M	40.7 M	40.7 M	40.7 M	40.7 M	24.5 M	24.5 M	24.5 M	24.5 M	17.4 M	17.4 M	17.4 M	17.4 M	18.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	33.6 M	31.1 M	35.8 M	41.8 M	47.8 M	51 M	52.2 M	57.4 M	61.2 M	66.7 M	74.8 M	84.5 M	39.5 M	45.3 M	22 M	22 M	22 M	22 M	7 M	7 M	7 M	7 M	186 K	186 K	186 K	186 K	1.37 M	-	-	-	142 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	38.7 M	37.1 M	38.1 M	44.7 M	50.7 M	55.3 M	60.1 M	63.7 M	-	75.6 M	80.2 M	88.3 M	43.2 M	63.6 M	38.8 M	38.8 M	38.8 M	38.8 M	23.6 M	23.6 M	23.6 M	23.6 M	16.5 M	16.5 M	16.5 M	16.5 M	18.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	38.7 M	36.3 M	37.3 M	43.9 M	50.7 M	55.3 M	60.1 M	63.7 M	69.9 M	75.6 M	80.2 M	88.3 M	43.2 M	63.6 M	38.8 M	38.8 M	38.8 M	38.8 M	23.6 M	23.6 M	23.6 M	23.6 M	16.5 M	16.5 M	16.5 M	16.5 M	18.1 M	-	-	-	-149 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency